Neurogene Inc. Stock Performance Update
Neurogene Inc. (ticker NGNE) closed the trading day at a price of USD 25.40, reflecting a 3.96 % increase during the 24‑hour period that ended at 05:05 AM Central European Time on Wednesday, 21 March 2026. The current market price places the share at roughly USD 25.4 on the major exchanges.
Market Overview
| Metric | Value |
|---|---|
| Market Capitalisation | USD 465.3 million |
| Shares Outstanding | 20 million |
| 24‑Hour Trading Volume | USD 5.8 million |
| 200‑Day Simple Moving Average | USD 27.46 |
| 52‑Week High | USD 43.66 (09 July 2026) |
| 52‑Week Low | USD 15.93 (02 May 2026) |
The company’s stock has fallen -25.79 % since the end of last month.
Recent Trading Activity of Peer Companies
| Company | Ticker | 24‑Hour Change | Current Price | Market Cap (USD m) | P/E Ratio |
|---|---|---|---|---|---|
| Cars | CARS | -0.39 % | USD 10.54 | 546.6 | 17.8 |
| Gamco Investors | GAMI | +1.61 % | USD 25.09 | 556.5 | 8.22 |
| Abrdn Income Credit Strat | ACP‑PA | -0.34 % | USD 17.80 | 557.1 | 7.29 |
| Tronox | TROX | -2.88 % | USD 3.39 | 554.2 | – |
| Phathom | PHAT | +1.30 % | USD 7.31 | 549.7 | – |
Company Profile
Neurogene Inc. is a biopharmaceutical company headquartered in New York, United States. The company specializes in the development of genetic medicines aimed at treating severe neurological diseases for patients and their families. Neurogene is listed on the Nasdaq stock exchange and completed its initial public offering on March 7, 2014. Its global customer base is served through its website at www.neurogene.com .
